Prosecution Insights
Prosecution Insights
17 pending office actions • 10 clients • 17 examiners • 13 art units • 0 of 17 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (6%) |
| §103 only | 2 (12%) |
| §112 only | 2 (12%) |
| Double-patenting only | 1 (6%) |
| Double-patenting + other | 6 (35%) |
| Multi-statute (no §101) | 4 (24%) |
| No statute on record | 1 (6%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LIU, TRACY | 1 | 54.5% | +27.0% |
| COFFA, SERGIO | 1 | 61.2% | +33.1% |
| KATAKAM, SUDHAKAR | 1 | 74.7% | +23.5% |
| DABKOWSKI, ERINNE R | 1 | 55.9% | +69.2% |
| CRAIG, KAILA ANGELIQUE | 1 | 32.8% | +26.5% |
| SIMMONS, CHRIS E | 1 | 34.5% | +19.3% |
| VALENROD, YEVGENY | 1 | 72.6% | +25.1% |
| HUANG, GIGI GEORGIANA | 1 | 31.7% | +30.6% |
| ISMAIL, REHANA | 1 | 77.0% | +32.8% |
| CHO, DAVID H | 1 | 37.5% | +73.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18936782 | HALIDE-FREE AMMONIUM SILANES | VALENROD, YEVGENY | 15d |
| 19275772 | ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF | CRAIG, KAILA ANGELIQUE | 33d |
| 18586086 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | CHO, DAVID H | — |
| 17983098 | TREATMENT OF METABOLIC DISORDERS THROUGH THE TARGETING OF A NOVEL CIRCULATING HORMONE COMPLEX | GERIDO, DWAN A | — |
| 17776912 | SYSTEMS AND METHODS PRODUCING SEEDED GRAFTS | GORDON, BRIAN R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19081912 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | SIMMONS, CHRIS E | 17d overdue |
| 18936782 | HALIDE-FREE AMMONIUM SILANES | VALENROD, YEVGENY | 15d |
| 19275772 | ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF | CRAIG, KAILA ANGELIQUE | 33d |
| 19329417 | CELL-PENETRATING PEPTIDE COMPOUNDS | DABKOWSKI, ERINNE R | 83d |
| 19427735 | QUATERNARY AMMONIUM SILANE AQUEOUS HYDROGEL FORMULATIONS | LIU, TRACY | — |
| 19329427 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | COFFA, SERGIO | — |
| 19329353 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | KATAKAM, SUDHAKAR | — |
| 18917928 | METHOD OF TREATING DIABETIC MACULAR EDEMA | HUANG, GIGI GEORGIANA | — |
| Art Unit | Apps |
|---|---|
| 1658 | 2 |
| 1615 | 2 |
| 1614 | 1 |
| 1654 | 1 |
| 1622 | 1 |
| 1628 | 1 |
| 1613 | 1 |
| 1699 | 1 |
| 1632 | 1 |
| 1629 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19427735 | QUATERNARY AMMONIUM SILANE AQUEOUS HYDROGEL FORMULATIONS | Topikos Scientific, Inc. | LIU, TRACY | 1614 | §103 | Non-Final OA | — | Pending | Dec 19, 2025 |
| 19329427 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | Ohio State Innovation Foundation | COFFA, SERGIO | 1658 | §102DP | Non-Final OA | — | Pending | Sep 15, 2025 |
| 19329353 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | Ohio State Innovation Foundation | KATAKAM, SUDHAKAR | 1658 | §112DP | Non-Final OA | — | Pending | Sep 15, 2025 |
| 19329417 | CELL-PENETRATING PEPTIDE COMPOUNDS | Ohio State Innovation Foundation | DABKOWSKI, ERINNE R | 1654 | §102§103§112DP | Non-Final OA | 83d | Pending | Sep 15, 2025 |
| 19275772 | ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF | Fennec Pharmaceuticals, Inc. | CRAIG, KAILA ANGELIQUE | 1615 | §103§112 | Final Rejection | 33d | Pending | Jul 21, 2025 |
| 19081912 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | Avilar Therapeutics, Inc. | SIMMONS, CHRIS E | 1622 | §112 | Non-Final OA | 17d overdue | Pending | Mar 17, 2025 |
| 18936782 | HALIDE-FREE AMMONIUM SILANES | Topikos Scientific, Inc. | VALENROD, YEVGENY | 1628 | §103§112 | Non-Final OA | 15d | Pending | Nov 04, 2024 |
| 18917928 | METHOD OF TREATING DIABETIC MACULAR EDEMA | Oculis Operations Sàrl | HUANG, GIGI GEORGIANA | 1613 | §103DP | Non-Final OA | — | Pending | Oct 16, 2024 |
| 18792377 | MULTIDOSE OPHTHALMIC COMPOSITIONS | Oculis Operations Sàrl | ISMAIL, REHANA | §103DP | Non-Final OA | — | Pending | Aug 01, 2024 | |
| 18586086 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | Avilar Therapeutics, Inc. | CHO, DAVID H | §103§112 | Non-Final OA | — | Pending | Feb 23, 2024 | |
| 18375162 | ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF | Fennec Pharmaceuticals Inc. | KWON, JOHN SEUNGJAI | 1615 | §103 | Non-Final OA | 3d overdue | Pending | Sep 29, 2023 |
| 18231091 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | Pharmacosmos Holding A/S | CRAIGO, BAHAR ALAWI | 1699 | Other | Non-Final OA | 7d | Pending | Aug 07, 2023 |
| 18229070 | VIRAL CONSTRUCTS FOR USE IN ENHANCING T-CELL PRIMING DURING VACCINATION | Leidos, Inc. | TAKENAKA, RISA | 1632 | §112 | Non-Final OA | — | Pending | Aug 01, 2023 |
| 18117983 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | Pharmacosmos Holding A/S | SHOWALTER, ALEXANDER KEITH | 1629 | DP | Final Rejection | — | Pending | Mar 06, 2023 |
| 17983098 | TREATMENT OF METABOLIC DISORDERS THROUGH THE TARGETING OF A NOVEL CIRCULATING HORMONE COMPLEX | The President and Fellows of Harvard College | GERIDO, DWAN A | 1797 | §101§112 | Non-Final OA | — | Pending | Nov 08, 2022 |
| 17776912 | SYSTEMS AND METHODS PRODUCING SEEDED GRAFTS | Research Institute AT Nationwide Children'S Hospital | GORDON, BRIAN R | 1798 | §102§103§112 | Final Rejection | — | Pending | May 13, 2022 |
| 17554940 | PATIENT SELECTION FOR ENHANCEMENT OF ANTI-TUMOR IMMUNITY IN CANCER PATIENTS | Pharmacosmos Holdings A/S | BAEK, BONG-SOOK | 1611 | §103§112DP | Final Rejection | — | Pending | Dec 17, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial